Literature DB >> 565192

Comparative haemodynamic effects of clonidine and guanfacine.

H F Oates, L M Stoker, E P MacCarthy, J C Monaghan, G S Stokes.   

Abstract

Dose-response relationships were established for the acute effects on arterial pressure and heart rate of the antihypertensive agents, clonidine and guanfacine, administered intravenously or intramuscularly to anaesthetized rats. The intramuscular route appeared to be preferable to the intravenous, for the direct pressor potency of each drug was thereby greatly reduced in relation to the hypotensive efficacy. The potency of clonidine was 10-20 times that of guanfacine, but the same maximal fall in blood pressure was obtained with either agent administered by either route. Both agents caused a marked, dose-related suppression of plasma renin activity. When either clonidine or guanfacine was administered twice daily for 3 weeks and then discontinued, a phase of blood pressure overshoot with tachycardia commenced within 24 hr of the last injection. These withdrawal effects were more evident in guanfacine-treated rats than in clonidine-treated rats.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 565192

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  3 in total

1.  Double-blind trial comparing guanfacine and methyldopa in patients with essential hypertension.

Authors:  A J Bune; J P Chalmers; J R Graham; P R Howe; M J West; L M Wing
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

2.  Guanfacine and clonidine: antihypertensive and withdrawal characteristics after continuous infusion and its interruption in the spontaneously hypertensive and normotensive rat.

Authors:  M J Thoolen; P B Timmermans; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-04       Impact factor: 3.000

Review 3.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.